(Q51829097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Arnout Voet

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Christine Helsen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kam Y J Zhang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

21 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

644-651

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

New strategies for medical management of castration-resistant prostate cancer.

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

The role of androgens and the androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Castration-resistant prostate cancer: locking up the molecular escape routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

New developments in castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Androgen receptor antagonists: a patent review (2008-2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Novel agents and new therapeutics in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

ZINC--a free database of commercially available compounds for virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Development and testing of a general amber force field

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Development and validation of a genetic algorithm for flexible docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Knowledge-based scoring function to predict protein-ligand interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

PROCHECK: a program to check the stereochemical quality of protein structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

The rules of DNA recognition by the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

AR, the cell cycle, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

7 January 2021

Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

7 January 2021

A role for selective androgen response elements in the development of the epididymis and the androgen control of the 5α reductase II gene

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

7 January 2021

DSX: a knowledge-based scoring function for the assessment of protein-ligand complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200549

7 January 2021

Identifiers

DOI

10.1002/CMDC.201200549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23436650%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference